JP2008528004A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528004A5
JP2008528004A5 JP2007552402A JP2007552402A JP2008528004A5 JP 2008528004 A5 JP2008528004 A5 JP 2008528004A5 JP 2007552402 A JP2007552402 A JP 2007552402A JP 2007552402 A JP2007552402 A JP 2007552402A JP 2008528004 A5 JP2008528004 A5 JP 2008528004A5
Authority
JP
Japan
Prior art keywords
nucleic acid
crt
acid molecule
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007552402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528004A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/002707 external-priority patent/WO2006081323A2/en
Publication of JP2008528004A publication Critical patent/JP2008528004A/ja
Publication of JP2008528004A5 publication Critical patent/JP2008528004A5/ja
Pending legal-status Critical Current

Links

JP2007552402A 2005-01-26 2006-01-26 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン Pending JP2008528004A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64715005P 2005-01-26 2005-01-26
US64734105P 2005-01-26 2005-01-26
PCT/US2006/002707 WO2006081323A2 (en) 2005-01-26 2006-01-26 Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin

Publications (2)

Publication Number Publication Date
JP2008528004A JP2008528004A (ja) 2008-07-31
JP2008528004A5 true JP2008528004A5 (enExample) 2009-03-19

Family

ID=36741036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552402A Pending JP2008528004A (ja) 2005-01-26 2006-01-26 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン

Country Status (5)

Country Link
US (1) US20080102084A1 (enExample)
EP (1) EP1846026A4 (enExample)
JP (1) JP2008528004A (enExample)
CA (1) CA2595726A1 (enExample)
WO (1) WO2006081323A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
EP1363660A4 (en) 2001-02-01 2006-06-21 Univ Johns Hopkins HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
RU2644201C2 (ru) 2011-12-21 2018-02-08 Вэксибоди Ас Вакцины против hpv
ES2871325T3 (es) * 2013-09-16 2021-10-28 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Composición de vacuna que comprende calreticulina mutante
MX348980B (es) 2013-09-16 2017-07-05 Cemm-Forschungszentrum Für Molekulare Medizin Gmbh Calreticulina mutante para la diagnosis de malignidades mieloides.
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
US20210169979A1 (en) * 2019-12-05 2021-06-10 The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges System and method for sonosensitized cancer immunotherapy with nanoparticles

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US4898730A (en) * 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US5582831A (en) * 1991-11-26 1996-12-10 Yeda Research And Development Co., Ltd. Anti-tumor vaccines
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
AU8762991A (en) * 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
PT523391E (pt) * 1991-07-13 2003-08-29 Dade Behring Marburg Gmbh Utilizacao dos peptidos derivados dos genes hpv-16 e6 e e7 para fins de diagnostico
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5997869A (en) * 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
US5426097A (en) * 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5854202A (en) * 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
CA2249354A1 (en) * 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
US6066716A (en) * 1996-09-20 2000-05-23 University Of New Mexico Purified heat shock protein complexes
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2291039T3 (es) * 1998-09-04 2008-02-16 Sanofi Pasteur Limited Tratamiento del cancer cervical.
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
US6734173B1 (en) * 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20010034042A1 (en) * 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
US7342002B2 (en) * 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
US20020065771A1 (en) * 2000-11-30 2002-05-30 International Business Machines Corporation System and method for merchant provided pre-printed checks
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
EP1363660A4 (en) * 2001-02-01 2006-06-21 Univ Johns Hopkins HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
JP2004535816A (ja) * 2001-07-20 2004-12-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｃｉｎを含むｈｐｖ関連の前癌性増殖および癌性増殖に関する方法および組成物
CN1720060B (zh) * 2002-10-03 2011-12-14 惠氏控股公司 人乳头瘤病毒多肽和免疫原性组合物
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein

Similar Documents

Publication Publication Date Title
CN107434827B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN104039833B (zh) 针对hpv的疫苗
AU2015255834B2 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2017529059A5 (enExample)
JP2004527213A5 (enExample)
JP2008528004A5 (enExample)
JP2016512213A5 (enExample)
CN103408669A (zh) Glp-1类似物融合蛋白，及其制备方法和用途
EP1644048B1 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
Zhao et al. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses
CN107847575A (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
US20140234316A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
EP2172488A1 (en) Material with immunogenicity
Fissolo Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein-capturing, viral J-domain
US20110236385A1 (en) Blocking mesothelin peptide fragments
Bleifuss et al. The translocation motif of hepatitis B virus improves protein vaccination
CN1948333B (zh) 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
US20250066443A1 (en) Compositions comprising truncated interleukin-33 and interleukin-2
CN1919873B (zh) 包含人HSP70 ATPase结构域与哺乳动物p53蛋白的融合蛋白及其应用
Bequet-Romero et al. Mutated variant of human vascular endothelial growth factor as a vaccine candidate for cancer immunotherapy